Skip to main content
BAX
NYSE Industrial Applications And Services

Baxter Q2 Sales Rise 5% Organic, Raises Full-Year EPS Guidance to $1.95-$2.15

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$26.25
Mkt Cap
$13.816B
52W Low
$15.73
52W High
$30
52W Position info
67% above low
Off High info
13% below high
Rel. Volume info
3.2× avg
Market data snapshot near publication time

BAX sits 67% above its 52-week low of $15.73 on elevated volume (3.2× avg).

Summary

Baxter International reported Q2 2026 sales of $2.96B (up 5% organic) and adjusted EPS of $0.56, beating expectations and raising full-year guidance. The quarter included a segment realignment, an IRS settlement, and tariff refunds, but the Novum LVP pump hold continues.


Key Events · Earnings and Guidance · BAX

  • Q2 Beat and Raise

    Sales of $2.96B grew 5% organically; adjusted EPS of $0.56 beat consensus. Full-year adjusted EPS guidance raised to $1.95-$2.15.

  • Segment Realignment

    Consolidated from three to two segments: Medical Products & Therapies and Healthcare Systems & Technologies. Prior periods recast.

  • IRS Settlement

    Settled 2019-2020 transfer pricing audit for amounts consistent with existing reserves; no adjustment to 2021-2025 reserves.

  • Tariff Refund Boost

    Recorded ~$75M in IEEPA tariff refunds in Q2, with $65M receivable. Additional refund claims expected but not material.


Analysis · BAX · Industrial Applications And Services

Baxter delivered a clean Q2 beat with $2.96B in sales (up 5% organic) and adjusted EPS of $0.56, well above consensus. The company raised its full-year adjusted EPS guidance to $1.95-$2.15, signaling confidence in the turnaround. The quarter also saw a segment realignment, an IRS settlement with no cash impact, and a $75M tariff refund boost. However, the Novum LVP pump remains under a shipment hold, and credit rating agencies have negative outlooks. The results show operational momentum but also highlight lingering regulatory and balance-sheet risks.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BAX was trading at $26.25 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $13.8B. The 52-week trading range was $15.73 to $30.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BAX - Latest Insights

BAX
Oct 29, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $22.94
Real-time Price: $25.43 info
Change: +$2.49 (+11%) info
Market Cap: $13.135B info
BAX
Oct 29, 2026, 8:06 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $26.00
Real-time Price: $25.43 info
Change: -$0.570 (-2%) info
Market Cap: $13.135B info
BAX
Oct 29, 2026, 7:18 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.74
Real-time Price: $25.43 info
Change: -$1.31 (-5%) info
Market Cap: $13.135B info
BAX
Oct 29, 2026, 7:15 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $26.50
Real-time Price: $25.43 info
Change: -$1.07 (-4%) info
Market Cap: $13.135B info
BAX
Aug 19, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $26.20
Real-time Price: $25.43 info
Change: -$0.770 (-3%) info
Market Cap: $13.135B info